Equities analysts predict that BRAINSWAY LTD/S (NASDAQ:BWAY) will announce ($0.12) earnings per share (EPS) for the current fiscal quarter, according to Zacks. Two analysts have issued estimates for BRAINSWAY LTD/S’s earnings, with estimates ranging from ($0.13) to ($0.11). The company is scheduled to announce its next earnings results on Monday, January 1st.
According to Zacks, analysts expect that BRAINSWAY LTD/S will report full-year earnings of ($0.52) per share for the current fiscal year, with EPS estimates ranging from ($0.54) to ($0.49). For the next year, analysts expect that the business will post earnings of ($0.36) per share, with EPS estimates ranging from ($0.42) to ($0.29). Zacks Investment Research’s earnings per share calculations are an average based on a survey of sell-side analysts that follow BRAINSWAY LTD/S.
BRAINSWAY LTD/S (NASDAQ:BWAY) last released its earnings results on Monday, August 26th. The company reported ($0.17) earnings per share (EPS) for the quarter, missing the Zacks’ consensus estimate of ($0.11) by ($0.06). The business had revenue of $5.70 million during the quarter, compared to analysts’ expectations of $5.30 million.
BRAINSWAY LTD/S stock traded up $0.18 during midday trading on Friday, reaching $10.37. The company’s stock had a trading volume of 1,221 shares, compared to its average volume of 7,468. BRAINSWAY LTD/S has a 52 week low of $8.00 and a 52 week high of $12.39. The firm’s 50-day moving average is $9.98.
Large investors have recently added to or reduced their stakes in the company. ARK Investment Management LLC bought a new stake in shares of BRAINSWAY LTD/S during the second quarter worth about $863,000. Delek Group Ltd. bought a new stake in shares of BRAINSWAY LTD/S during the second quarter worth about $3,176,000. Victory Capital Management Inc. bought a new stake in shares of BRAINSWAY LTD/S during the second quarter worth about $157,000. Finally, Noked Capital LTD acquired a new position in shares of BRAINSWAY LTD/S in the second quarter worth approximately $572,000. Institutional investors own 10.84% of the company’s stock.
About BRAINSWAY LTD/S
Brainsway Ltd. engages in the development and provision of technology solutions for non-invasive treatment of brain disorders in Israel and internationally. It offers deep transcranial magnetic stimulation systems for treating various conditions, including autism, Alzheimer's disease, bipolar disorders, chronic pains, depressive disorders, Parkinson's diseases, schizophrenia, smoking cessation, post-traumatic stress disorders, multiple sclerosis, obsessive compulsive disorders, and stroke rehabilitation.
Featured Article: What is a death cross?
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for BRAINSWAY LTD/S Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for BRAINSWAY LTD/S and related companies with MarketBeat.com's FREE daily email newsletter.